What Is the Treatment of Chickenpox? Oral Antiviral Therapy and Symptomatic Management
Chickenpox requires timely clinical assessment — particularly in patients who present early, when the disease is still evolving and targeted antiviral intervention offers the greatest benefit.
Treatment Approach
The first-line approach combines a course of oral antiviral therapy — with agent selection informed by bioavailability — alongside symptomatic relief measures addressing itch, mucosal discomfort, and skin irritation. The full regimen details and sequencing are in the structured protocol.
Clinical Goals
Settling of fever and cessation of new vesicle formation, with no persisting fever or new vesicles beyond 6 days after onset.
References
DOI: 10.1016/j.jinf.2008.03.004
- While it is rare for patients to present within such a short time frame, a pragmatic approach is to consider antiviral agents in patients who present within 24–48 h of new vesicles, implying that the disease is still evolving.
- However, the bioavailability of oral aciclovir is poor, requiring dosing at 800 mg 5 times daily.
- The pro-drug valaciclovir, at a dose of 1 g 3 times daily, greatly enhances bioavailability, resulting in 3- to 4-fold higher plasma aciclovir levels that can be achieved with oral aciclovir.
- Famciclovir, the pro-drug of penciclovir, dosed at 500 mg 3 times daily, also has enhanced bioavailability when compared with aciclovir.
- A minimum of 1 week of antiviral therapy is recommended.
- Supportive therapy, such as anti-pruritic drugs can be helpful for all age groups.
- Mouthwashes and soothing topical lotions, plus anaesthetic gels for the genital area if there is mucosal involvement, are also useful for symptomatic treatment.
- Persisting fever with new vesicles >6 days after onset.
View source ↗